Syndax Pharmaceuticals, Inc. (SNDX)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

SNDX Syndax Pharmaceuticals, Inc.

盘后交易 12-20 16:26:08 EST

13.08

+0.23

+1.79%

盘后13.08

+0.000.00%

16:20 EST

最高13.15	最低12.76	成交量499.33万
今开12.78	昨收12.85	日振幅3.03%
总市值11.16亿	流通市值10.36亿	总股本8,536万
成交额6,465万	换手率6.31%	流通股本7,918万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"SNDX","market":"US","secType":"STK","nameCN":"Syndax Pharmaceuticals, Inc. ","latestPrice":13.08,"timestamp":1734728399999,"preClose":12.85,"halted":0,"volume":4993261,"hourTrading":{"tag":"盘后","latestPrice":13.08,"preClose":13.08,"latestTime":"16:20 EST","volume":369766,"amount":4836540.389297999,"timestamp":1734729600634},"delay":0,"floatShares":79175431,"shares":85357675,"eps":-3.621743,"marketStatus":"盘后交易","marketStatusCode":4,"change":0.23,"latestTime":"12-20 16:26:08 EST","open":12.78,"high":13.15,"low":12.76,"amount":64654900.516752005,"amplitude":0.03035,"askPrice":13.5,"askSize":200,"bidPrice":12.5,"bidSize":212,"shortable":3,"etf":0,"ttmEps":-3.621743,"exchange":"NASDAQ","tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1734742800000},"adr":0,"listingDate":1456981200000,"adjPreClose":12.85,"adrRate":0,"preHourTrading":{"tag":"盘前","latestPrice":12.84,"preClose":12.85,"latestTime":"09:29 EST","volume":1356,"amount":17433.976740000002,"timestamp":1734704999999},"postHourTrading":{"tag":"盘后","latestPrice":13.08,"preClose":13.08,"latestTime":"16:20 EST","volume":369766,"amount":4836540.389297999,"timestamp":1734729600634},"volumeRatio":1.564691,"impliedVol":0.6849,"impliedVolPercentile":0.5516},"requestUrl":"/m/hq/s/SNDX","defaultTab":"news","newsList":[{"id":"2492023989","title":"美国研究综述-多米诺比萨、霍尼韦尔、沃尔玛","url":"https://stock-news.laohu8.com/highlight/detail?id=2492023989","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492023989?lang=zh_cn&edition=full","pubTime":"2024-12-17 15:19","pubTimestamp":1734419971,"startTime":"0","endTime":"0","summary":"美国研究综述-多米诺比萨、霍尼韦尔、沃尔玛路透12月17日 - 华尔街证券分析师周二调整了对包括多米诺比萨、霍尼韦尔和沃尔玛在内的几家美国上市公司的评级和目标价。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241217:nL4S3NI0HC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1585245621.USD","CMCSA","COGT","HON","LU0648001328.SGD","NPCE","WMT","RARE","PRVA","TLRY","BK4507","BHLB","POST","RGEN","BVS","MD","TMDX","TOL","NBIX","BK4500","COST","HCSG","BK4007","DPZ","LU2125154935.USD","LW","SNDX","BK4596","TXRH","ALEC","WEN","AGL","IE00BZ1G4Q59.USD","MOFG","OLMA","ACI","BK4082","PLNT","BK4602","CMG","ALGT","ZBH","JACK","BK4597","LU2505996509.AUD","LU2108987350.USD","ASTH"],"gpt_icon":1},{"id":"2491669358","title":"Syndax Pharmaceuticals, Inc.盘中异动 股价大跌5.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2491669358","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491669358?lang=zh_cn&edition=full","pubTime":"2024-12-13 02:31","pubTimestamp":1734028286,"startTime":"0","endTime":"0","summary":"北京时间2024年12月13日02时31分，Syndax Pharmaceuticals, Inc.股票出现异动，股价快速跳水5.06%。Syndax Pharmaceuticals, Inc.股票所在的生物技术行业中，整体跌幅为1.03%。其相关个股中，Trevi Therapeutics, Inc.、Cero Therapeutics Holdings Inc C/Wts 13/02/2029 、Palisade Bio, Inc.涨幅较大，Palisade Bio, Inc.、Aptevo Therapeutics Inc.、Conduit Pharmaceuticals Inc.较为活跃，换手率分别为3947.60%、1101.15%、90.12%，振幅较大的相关个股有Neurosense Therapeutics Ltd C/Wts 10/11/2026 、Palisade Bio, Inc.、Aptevo Therapeutics Inc.，振幅分别为129.16%、99.29%、95.90%。Syndax Pharmaceuticals, Inc.公司简介：Syndax Pharmaceuticals Inc是一家临床阶段的生物制药公司，致力于开发多种癌症适应症的联合疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241213023126a1e9bb04&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241213023126a1e9bb04&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","SNDX"],"gpt_icon":0},{"id":"2490023042","title":"健康巡回：新型联合疗法有望治疗血癌","url":"https://stock-news.laohu8.com/highlight/detail?id=2490023042","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490023042?lang=zh_cn&edition=full","pubTime":"2024-12-11 04:36","pubTimestamp":1733863013,"startTime":"0","endTime":"0","summary":"三联药物疗法有望治疗血癌 研究人员在美国血液学学会  会议上报告说，新型三联药物疗法有望治疗各种白血病患者。该疗法的总体反应率为 82%。\"我们看到的结果确实将这种三联疗法定位为一种潜在的标准治疗方案。\"如今，我们有几位患者已经不再接受治疗，而是通过定期的血液MRD检测进行监测。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241210:nL4S3NB1LV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2347655156.SGD","LU1496350502.SGD","LU0310799852.SGD","LU0553294199.USD","LU0820561818.USD","LU1003077747.HKD","LU1074936037.SGD","LU2461242641.AUD","SG9999017495.SGD","LU1035775433.USD","BK4559","LU0109391861.USD","IE00B2B36J28.USD","LU2324357040.USD","LLY","LU2133065610.SGD","BK4139","LU1023059063.AUD","LU1323610961.USD","SGXZ31699556.SGD","LU0006306889.USD","LU0029864427.USD","LU0225771236.USD","IE00BSNM7G36.USD","SNDX","LU1551013425.SGD","LU0965509101.SGD","LU1261432733.SGD","LU2237443382.USD","LU1712237335.SGD","LU0738911758.USD","LU2237443622.USD","SG9999018865.SGD","IE00B3PB1722.GBP","LU0823416689.USD","SG9999015952.SGD","LU2491050071.SGD","IE00BVYPNV92.GBP","BMY","LU2360032135.SGD","LU0965509010.AUD","LU1366192091.USD","LU2125154778.USD","LU1732799900.SGD","LU2242652126.USD","ABBV","LU2264538146.SGD","SG9999015978.USD","IE00B4R5TH58.HKD","LU0079474960.USD"],"gpt_icon":1},{"id":"2490017725","title":"Syndax Pharmaceuticals, Inc.盘中异动 大幅下跌5.08%报14.77美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2490017725","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490017725?lang=zh_cn&edition=full","pubTime":"2024-12-10 23:26","pubTimestamp":1733844364,"startTime":"0","endTime":"0","summary":"北京时间2024年12月10日23时26分，Syndax Pharmaceuticals, Inc.股票出现波动，股价快速下挫5.08%。Syndax Pharmaceuticals, Inc.股票所在的生物技术行业中，整体跌幅为1.29%。其相关个股中，Chimerix, Inc.、60 Degrees Pharmaceuticals Inc C/Wts 12/07/2028 、Newamsterdam Pharma Co Nv C/Wts 涨幅较大，Psyence Biomedical Ltd.、Processa Pharmaceuticals, Inc.、Chimerix, Inc.较为活跃，换手率分别为1911.49%、437.09%、121.63%，振幅较大的相关个股有Chimerix, Inc.、Klotho Neurosciences Inc C/Wts 21/06/2029 、Uniqure N.V.，振幅分别为154.91%、131.78%、42.77%。Syndax Pharmaceuticals, Inc.公司简介：Syndax Pharmaceuticals Inc是一家临床阶段的生物制药公司，致力于开发多种癌症适应症的联合疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241210232604a1e3b184&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241210232604a1e3b184&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","SNDX"],"gpt_icon":0},{"id":"2490977608","title":"Syndax Pharmaceuticals, Inc.盘中异动 早盘股价大跌5.21%","url":"https://stock-news.laohu8.com/highlight/detail?id=2490977608","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490977608?lang=zh_cn&edition=full","pubTime":"2024-12-09 23:13","pubTimestamp":1733757212,"startTime":"0","endTime":"0","summary":"北京时间2024年12月09日23时13分，Syndax Pharmaceuticals, Inc.股票出现异动，股价快速下跌5.21%。Syndax Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.95%。其相关个股中，60 Degrees Pharmaceuticals Inc C/Wts 12/07/2028 、Reviva Pharmaceuticals Holdings Inc C/Wts 25/12/2025、Conduit Pharmaceuticals Inc C/Wts 22/09/2028涨幅较大，Sonnet Biotherapeutics Holdings, Inc.、Dermata Therapeutics, Inc.、Entero Therapeutics Inc.较为活跃，换手率分别为4406.83%、34.55%、29.31%，振幅较大的相关个股有Reviva Pharmaceuticals Holdings Inc C/Wts 25/12/2025、Sonnet Biotherapeutics Holdings, Inc.、Psyence Biomedical Ltd C/Wts 25/01/2029，振幅分别为141.61%、75.24%、54.05%。Syndax Pharmaceuticals, Inc.公司简介：Syndax Pharmaceuticals Inc是一家临床阶段的生物制药公司，致力于开发多种癌症适应症的联合疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024120923133295e86a77&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024120923133295e86a77&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SNDX","BK4139"],"gpt_icon":0},{"id":"2489846727","title":"Syndax Pharmaceuticals, Inc.盘中异动 股价大跌5.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2489846727","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2489846727?lang=zh_cn&edition=full","pubTime":"2024-12-06 01:01","pubTimestamp":1733418081,"startTime":"0","endTime":"0","summary":"北京时间2024年12月06日01时01分，Syndax Pharmaceuticals, Inc.股票出现波动，股价快速下挫5.08%。Syndax Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.39%。其相关个股中，Protara Therapeutics, Inc.、Conduit Pharmaceuticals Inc C/Wts 22/09/2028、Molecular Templates, Inc.涨幅较大，Molecular Templates, Inc.、Psyence Biomedical Ltd.、Protara Therapeutics, Inc.较为活跃，换手率分别为3229.10%、2318.16%、455.91%，振幅较大的相关个股有Molecular Templates, Inc.、Nls Pharmaceutics Ltd C/Wts 02/02/2026、Protara Therapeutics, Inc.，振幅分别为124.83%、120.00%、106.21%。Syndax Pharmaceuticals, Inc.公司简介：Syndax Pharmaceuticals Inc是一家临床阶段的生物制药公司，致力于开发多种癌症适应症的联合疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241206010122971be7db&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241206010122971be7db&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","SNDX"],"gpt_icon":0},{"id":"2486035813","title":"Syndax Pharmaceuticals, Inc.盘中异动 快速上涨5.03%报16.90美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2486035813","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486035813?lang=zh_cn&edition=full","pubTime":"2024-11-25 23:05","pubTimestamp":1732547141,"startTime":"0","endTime":"0","summary":"北京时间2024年11月25日23时05分，Syndax Pharmaceuticals, Inc.股票出现波动，股价快速拉升5.03%。Syndax Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为1.71%。其相关个股中，Alpha Tau Medical Ltd C/Wts 、Ocean Biomedical Inc C/Wts 14/02/2028 、Conduit Pharmaceuticals Inc C/Wts 22/09/2028涨幅较大，Cognition Therapeutics, Inc.、木薯科学、Citius Pharmaceuticals, Inc.较为活跃，换手率分别为96.49%、91.35%、54.41%，振幅较大的相关个股有Apollomics Inc C/Wts 01/04/2028 、180 Life Sciences Corp C/Wts 07/11/2025、Ocean Biomedical Inc C/Wts 14/02/2028 ，振幅分别为55.45%、48.93%、47.19%。Syndax Pharmaceuticals, Inc.公司简介：Syndax Pharmaceuticals Inc是一家临床阶段的生物制药公司，致力于开发多种癌症适应症的联合疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024112523054298e446d8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024112523054298e446d8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","SNDX"],"gpt_icon":0},{"id":"2485189454","title":"Syndax Pharmaceuticals, Inc.盘中异动 快速下跌5.14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2485189454","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485189454?lang=zh_cn&edition=full","pubTime":"2024-11-21 23:00","pubTimestamp":1732201236,"startTime":"0","endTime":"0","summary":"北京时间2024年11月21日23时00分，Syndax Pharmaceuticals, Inc.股票出现波动，股价大幅跳水5.14%。Syndax Pharmaceuticals, Inc.股票所在的生物技术行业中，整体跌幅为0.41%。其相关个股中，Conduit Pharmaceuticals Inc C/Wts 22/09/2028、Silexion Therapeutics Corp C/Wts Exp 15/08/2029 、Pasithea Therapeutics Corp C/Wts 12/08/2026 涨幅较大，Conduit Pharmaceuticals Inc.、Biodexa Pharmaceuticals Plc、Tff Pharmaceuticals, Inc.较为活跃，换手率分别为387.15%、64.55%、52.41%，振幅较大的相关个股有Conduit Pharmaceuticals Inc C/Wts 22/09/2028、Silexion Therapeutics Corp C/Wts Exp 15/08/2029 、Klotho Neurosciences Inc C/Wts 21/06/2029 ，振幅分别为141.46%、76.33%、68.00%。Syndax Pharmaceuticals, Inc.公司简介：Syndax Pharmaceuticals Inc是一家临床阶段的生物制药公司，致力于开发多种癌症适应症的联合疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024112123003698e43f14&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024112123003698e43f14&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SNDX","BK4139"],"gpt_icon":0},{"id":"2484612671","title":"Syndax Pharmaceuticals, Inc.盘中异动 早盘急速上涨5.21%报16.66美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2484612671","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484612671?lang=zh_cn&edition=full","pubTime":"2024-11-18 22:31","pubTimestamp":1731940273,"startTime":"0","endTime":"0","summary":"北京时间2024年11月18日22时31分，Syndax Pharmaceuticals, Inc.股票出现波动，股价急速拉升5.21%。Syndax Pharmaceuticals, Inc.股票所在的生物技术行业中，整体跌幅为0.22%。其相关个股中，Hcw Biologics Inc.、冠科美博、Tc Biopharm  Plc C/Wts 10/02/2028 涨幅较大，Tharimmune, Inc.、Hcw Biologics Inc.、冠科美博较为活跃，换手率分别为514.42%、178.51%、174.93%，振幅较大的相关个股有Virpax Pharmaceuticals, Inc.、Innate Pharma、Moolec Science Sa，振幅分别为11.85%、10.42%、9.06%。Syndax Pharmaceuticals, Inc.公司简介：Syndax Pharmaceuticals Inc是一家临床阶段的生物制药公司，致力于开发多种癌症适应症的联合疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241118223113971a7247&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241118223113971a7247&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","SNDX"],"gpt_icon":0},{"id":"2484661939","title":"美国研究综述-Airbnb、Post Holdings、Syndax Pharmaceuticals","url":"https://stock-news.laohu8.com/highlight/detail?id=2484661939","media":"路透中文","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484661939?lang=zh_cn&edition=full","pubTime":"2024-11-18 15:15","pubTimestamp":1731914144,"startTime":"0","endTime":"0","summary":"美国研究综述-Airbnb、Post Holdings、Syndax Pharmaceuticals路透11月18日 - 华尔街证券分析师周一调整了对几家美国上市公司的评级和目标价，其中包括 Airbnb、Post Holdings 和 Syndax Pharmaceuticals。* Post Holdings Inc POST.N：摩根大通将目标价从125美元上调至135美元 * Syndax Pharmaceuticals Inc SNDX.O：杰富瑞将目标价从37美元上调至43美元 * Transmedics Group Inc TMDX.O：TD Cowen将目标价从175美元下调至120美元以下是路透周一报道的美国公司研究报告摘要。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241118:nL4S3MP0GY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1688375341.USD","POST","BK1521","CAPR","HK0000306701.USD","HBBD.SI","LU0348788117.USD","MBI","LU1196710864.SGD","SNDX","89988","LU1481107354.HKD","LU1983260115.SGD","LU0345776255.USD","LU0898667661.SGD","PCOR","ABNB","PGR","LU0737861772.HKD","TARS","09988","LU2355687059.USD","EFXT","LU0051755006.USD","IE00BFMHRM44.USD","LU1439103000.SGD","YELP","LU1105468828.SGD","KRRO","ADSK","LU0287142896.SGD","BK4503","IE00BZ08YT58.USD","LU0293314216.USD","LU1048588211.SGD","LU0251144936.SGD","LU0541502299.USD","LU0543330566.HKD","BABA","IE00B19Z9Z06.USD","BK1502","LU0543330483.HKD","PLD","INO","LU0516422440.USD","LU1023057109.AUD","LU0228367735.SGD","OVV","IE00BZ08YR35.GBP","TMDX"],"gpt_icon":1},{"id":"2483327055","title":"美国 FDA 批准 Syndax 的血癌药物","url":"https://stock-news.laohu8.com/highlight/detail?id=2483327055","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483327055?lang=zh_cn&edition=full","pubTime":"2024-11-16 07:24","pubTimestamp":1731713063,"startTime":"0","endTime":"0","summary":"路透11月15日 - 美国食品和药物管理局周五批准了Syndax Pharmaceuticals公司SNDX.O用于治疗成人和儿童血癌患者的药物，该公司股价在盘后交易中上涨了3%。该药物的批准是基于一项有104名患者参加的早中期试验，结果显示21%的患者病情完全缓解，特定血细胞水平部分恢复。Syndax公司预计，110毫克和160毫克的Revuforj片剂将于本月在美国上市。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241115:nL4T3MM1M7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SNDX","BK4550","BK4585","BK4532","BK4588","BK4139","INCY"],"gpt_icon":0},{"id":"2483532998","title":"BUZZ-Syndax 因血癌药物获 FDA 批准而上涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2483532998","media":"路透中文","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483532998?lang=zh_cn&edition=full","pubTime":"2024-11-16 07:14","pubTimestamp":1731712471,"startTime":"0","endTime":"0","summary":"BUZZ-Syndax 因血癌药物获 FDA 批准而上涨11月15日 -  ** 制药公司Syndax Pharmaceuticals SNDX.O的股价在盘后交易中上涨2%，达到16.11美元。** 美国 FDA 批准 Revumenib用于治疗带有 KMT2A 易位的急性白血病。** KMT2A 易位是涉及 KMT2A 基因的染色体重排，在约 10% 的急性白血病中发现这种情况 ** 批准基于一项早中期试验，该试验显示 21% 的患者病情完全缓解，特定血细胞水平部分恢复。** Syndax预计将于11月在美国推出110毫克和160毫克的Revuforj片剂供订购。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241115:nL4S3MM1LY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SNDX"],"gpt_icon":0},{"id":"2483585847","title":"Syndax Pharmaceuticals, Inc.盘中异动 下午盘大幅下挫5.09%报15.94美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2483585847","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483585847?lang=zh_cn&edition=full","pubTime":"2024-11-16 02:10","pubTimestamp":1731694206,"startTime":"0","endTime":"0","summary":"北京时间2024年11月16日02时10分，Syndax Pharmaceuticals, Inc.股票出现波动，股价急速下跌5.09%。Syndax Pharmaceuticals, Inc.股票所在的生物技术行业中，整体跌幅为3.50%。其相关个股中，Cero Therapeutics Holdings, Inc.、Seastar Medical Holding Corp C/Wts 28/10/2027 、Tc Biopharm  Plc C/Wts 10/02/2028 涨幅较大，Tc Biopharm  Plc、Cero Therapeutics Holdings, Inc.、Elevai Labs, Inc.较为活跃，换手率分别为4402.36%、698.15%、557.85%，振幅较大的相关个股有Silexion Therapeutics Corp C/Wts Exp 15/08/2029 、Cero Therapeutics Holdings Inc C/Wts 13/02/2029 、Celularity Inc C/Wts 16/07/2026 ，振幅分别为134.58%、129.73%、110.59%。Syndax Pharmaceuticals, Inc.公司简介：Syndax Pharmaceuticals Inc是一家临床阶段的生物制药公司，致力于开发多种癌症适应症的联合疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024111602100698e43039&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024111602100698e43039&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SNDX","BK4139"],"gpt_icon":0},{"id":"2483666386","title":"Syndax Pharmaceuticals, Inc.盘中异动 早盘大幅上涨5.11%报17.48美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2483666386","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483666386?lang=zh_cn&edition=full","pubTime":"2024-11-15 00:20","pubTimestamp":1731601208,"startTime":"0","endTime":"0","summary":"北京时间2024年11月15日00时20分，Syndax Pharmaceuticals, Inc.股票出现波动，股价急速拉升5.11%。Syndax Pharmaceuticals, Inc.股票所在的生物技术行业中，整体跌幅为0.52%。其相关个股中，Molecular Templates, Inc.、Psyence Biomedical Ltd C/Wts 25/01/2029、Pulmatrix, Inc.涨幅较大，Elevai Labs, Inc.、Molecular Templates, Inc.、Pulmatrix, Inc.较为活跃，换手率分别为2954.41%、1436.61%、327.72%，振幅较大的相关个股有Molecular Templates, Inc.、Pulmatrix, Inc.、Psyence Biomedical Ltd C/Wts 25/01/2029，振幅分别为181.37%、112.92%、86.36%。Syndax Pharmaceuticals, Inc.公司简介：Syndax Pharmaceuticals Inc是一家临床阶段的生物制药公司，致力于开发多种癌症适应症的联合疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241115002008a23812c7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241115002008a23812c7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SNDX","BK4139"],"gpt_icon":0},{"id":"2483038330","title":"BUZZ-Syndax Pharma 因癌症治疗数据未达到 \"更高的预期标准 \"而下跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2483038330","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483038330?lang=zh_cn&edition=full","pubTime":"2024-11-13 00:15","pubTimestamp":1731428111,"startTime":"0","endTime":"0","summary":"BUZZ-Syndax Pharma 因癌症治疗数据未达到 \"更高的预期标准 \"而下跌11月12日 -  ** 药物开发商Syndax Pharmaceuticals SNDX.O股价下跌21.4%，至17.13美元，为近一年来最低点  ** 公司报告了癌症疗法的中期研究结果  ** Syndax称，该疗法的完全缓解率为23%，部分血液学恢复率为  ** 公司称，试验中11%的患者出现了严重的治疗相关不良事件，2%的患者出现了可能危及生命的事件  ** BTIG 分析师 Justin Zelin 说，今天股价疲软的原因是 \"从公司上次更新的情况来看，公司的形象受到了损害\"。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241112:nL4T3MJ1WR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SNDX"],"gpt_icon":0},{"id":"2482083627","title":"Syndax Pharmaceuticals, Inc.盘中异动 早盘股价大跌24.47%","url":"https://stock-news.laohu8.com/highlight/detail?id=2482083627","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482083627?lang=zh_cn&edition=full","pubTime":"2024-11-12 22:30","pubTimestamp":1731421824,"startTime":"0","endTime":"0","summary":"北京时间2024年11月12日22时30分，Syndax Pharmaceuticals, Inc.股票出现异动，股价大幅跳水24.47%。Syndax Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.00%。其相关个股中，Geovax Labs Inc C/Wts 29/09/2025、Cero Therapeutics Holdings, Inc.、Tc Biopharm  Plc C/Wts 10/02/2028 涨幅较大，Geovax Labs, Inc.、Cero Therapeutics Holdings, Inc.、Elevai Labs, Inc.较为活跃，换手率分别为103.77%、59.19%、43.20%，振幅较大的相关个股有Plus Therapeutics, Inc.、Enveric Biosciences, Inc.、Curevac N.V.，振幅分别为5.88%、5.45%、5.37%。Syndax Pharmaceuticals, Inc.公司简介：Syndax Pharmaceuticals Inc是一家临床阶段的生物制药公司，致力于开发多种癌症适应症的联合疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024111222302598e420ec&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024111222302598e420ec&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SNDX","BK4139"],"gpt_icon":0},{"id":"2482267314","title":"Syndax Pharmaceuticals, Inc.2024财年第三财季实现净利润-84.13百万美元，同比减少64.48%","url":"https://stock-news.laohu8.com/highlight/detail?id=2482267314","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482267314?lang=zh_cn&edition=full","pubTime":"2024-11-11 00:01","pubTimestamp":1731254493,"startTime":"0","endTime":"0","summary":"11月11日，Syndax Pharmaceuticals, Inc.公布财报，公告显示公司2024财年第三财季净利润为-84.13百万美元，同比减少64.48%；其中营业收入为12.50百万美元，每股基本收益为-0.98美元。机构评级：截至2024年11月11日，当前有14家机构对Syndax Pharmaceuticals, Inc.目标价做出预测，其中目标均价为35.86美元，其中最低目标价为23.00美元，最高目标价为47.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241111000212abb36320&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241111000212abb36320&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SNDX"],"gpt_icon":0},{"id":"2480180918","title":"Syndax Pharmaceuticals Inc    预计每股亏损 1.11 美元 - 财报前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2480180918","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480180918?lang=zh_cn&edition=full","pubTime":"2024-11-02 12:09","pubTimestamp":1730520570,"startTime":"0","endTime":"0","summary":"   * Syndax Pharmaceuticals Inc    将于11月5日公布截至2024年9月30日的财报，预计该公司的季度收入将有所增长。* 根据LSEG的数据，9位分析师的平均预期显示，这家总部位于马萨诸塞州沃尔瑟姆的公司预计将实现1119.9万美元的营收。* LSEG 分析师对 Syndax Pharmaceuticals Inc 的平均预期是每股亏损 1.11 美元。* 华尔街对 Syndax Pharmaceuticals Inc 的 12 个月目标价中位数为 35.00 美元，高于其最新收盘价 18.98 美元。11月2日 - 上一季度业绩。除非另有说明，否则所有数据均以美元为单位。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Syndax Pharmaceuticals Inc    预计每股亏损 1.11 美元 - 财报前瞻","news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SNDX"],"gpt_icon":0},{"id":"2474041283","title":"Syndax Pharmaceuticals, Inc.盘中异动 临近收盘股价大涨5.00%报19.11美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2474041283","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2474041283?lang=zh_cn&edition=full","pubTime":"2024-10-12 03:33","pubTimestamp":1728675235,"startTime":"0","endTime":"0","summary":"北京时间2024年10月12日03时33分，Syndax Pharmaceuticals, Inc.股票出现波动，股价急速上涨5.00%。截至发稿，该股报19.11美元/股，成交量29.4292万股，换手率0.35%，振幅5.08%。Syndax Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为1.23%。Syndax Pharmaceuticals, Inc.公司简介：Syndax Pharmaceuticals Inc是一家临床阶段的生物制药公司，致力于开发多种癌症适应症的联合疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202410120333559719fbf6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202410120333559719fbf6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","SNDX"],"gpt_icon":0},{"id":"2470031057","title":"Syndax Pharmaceuticals, Inc.盘中异动 股价大涨5.31%报19.13美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2470031057","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2470031057?lang=zh_cn&edition=full","pubTime":"2024-09-28 00:59","pubTimestamp":1727456343,"startTime":"0","endTime":"0","summary":"北京时间2024年09月28日00时59分，Syndax Pharmaceuticals, Inc.股票出现异动，股价急速上涨5.31%。Syndax Pharmaceuticals, Inc.股票所在的生物技术行业中，整体跌幅为0.80%。其相关个股中，Nls Pharmaceutics Ltd C/Wts 02/02/2026、Onconetix, Inc.、Psyence Biomedical Ltd C/Wts 25/01/2029涨幅较大，Onconetix, Inc.、Seelos Therapeutics, Inc.、Tonix Pharmaceuticals Holding Corp.较为活跃，换手率分别为4232.85%、260.28%、133.96%，振幅较大的相关个股有Pasithea Therapeutics Corp C/Wts 12/08/2026 、Estrella Immunopharma Inc C/Wts 29/09/2028、Estrella Immunopharma, Inc.，振幅分别为167.75%、69.81%、65.94%。Syndax Pharmaceuticals, Inc.公司简介：Syndax Pharmaceuticals Inc是一家临床阶段的生物制药公司，致力于开发多种癌症适应症的联合疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240928005903a1dd1793&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240928005903a1dd1793&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","SNDX"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.syndax.com","stockEarnings":[{"period":"1week","weight":-0.046},{"period":"1month","weight":-0.1852},{"period":"3month","weight":-0.2967},{"period":"6month","weight":-0.3591},{"period":"1year","weight":-0.3477},{"period":"ytd","weight":-0.4054}],"compareEarnings":[{"period":"1week","weight":-0.0302},{"period":"1month","weight":-0.0071},{"period":"3month","weight":0.0314},{"period":"6month","weight":0.0764},{"period":"1year","weight":0.2517},{"period":"ytd","weight":0.2331}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Syndax Pharmaceuticals, Inc.于2005年10月11日根据特拉华州法律注册成立。该公司是一家临床阶段的生物制药公司，正在开发癌症疗法的创新管道。该公司正在开发revumenib，这是一种有效的、选择性的、menin-MLL结合相互作用的小分子抑制剂，用于治疗KMT2A重排或KMT2AR，也称为混合谱系白血病重排或MLLR，包括急性淋巴细胞白血病或ALL在内的急性白血病，以及急性髓细胞白血病或AML，以及necleophosmin 1，也称为NPM1，突变AML。","yearOnYearQuotes":[{"month":1,"riseRate":0.625,"avgChangeRate":0.044305},{"month":2,"riseRate":0.625,"avgChangeRate":0.07889},{"month":3,"riseRate":0.625,"avgChangeRate":0.084467},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.000613},{"month":5,"riseRate":0.444444,"avgChangeRate":0.006686},{"month":6,"riseRate":0.555556,"avgChangeRate":0.008456},{"month":7,"riseRate":0.555556,"avgChangeRate":0.011483},{"month":8,"riseRate":0.555556,"avgChangeRate":0.046113},{"month":9,"riseRate":0.555556,"avgChangeRate":-0.028471},{"month":10,"riseRate":0.222222,"avgChangeRate":-0.074254},{"month":11,"riseRate":0.555556,"avgChangeRate":0.001387},{"month":12,"riseRate":0.444444,"avgChangeRate":0.030802}],"exchange":"NASDAQ","name":"Syndax Pharmaceuticals, Inc. ","nameEN":"Syndax Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Syndax Pharmaceuticals, Inc. (SNDX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Syndax Pharmaceuticals, Inc. (SNDX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Syndax Pharmaceuticals, Inc. ,SNDX,Syndax Pharmaceuticals, Inc. 股票,Syndax Pharmaceuticals, Inc. 股票老虎,Syndax Pharmaceuticals, Inc. 股票老虎国际,Syndax Pharmaceuticals, Inc. 行情,Syndax Pharmaceuticals, Inc. 股票行情,Syndax Pharmaceuticals, Inc. 股价,Syndax Pharmaceuticals, Inc. 股市,Syndax Pharmaceuticals, Inc. 股票价格,Syndax Pharmaceuticals, Inc. 股票交易,Syndax Pharmaceuticals, Inc. 股票购买,Syndax Pharmaceuticals, Inc. 股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Syndax Pharmaceuticals, Inc. (SNDX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Syndax Pharmaceuticals, Inc. (SNDX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}